South Africa Cancer Immunotherapy Market Size & Outlook

Monoclonal antibodies was the largest segment with a revenue share of 66.55% in 2023. Horizon Databook has segmented the South Africa cancer immunotherapy market based on monoclonal antibodies, check point inhibitors, oncolytic viral therapies and cancer vaccines covering the revenue growth of each sub-segment from 2018 to 2030.

Advancements in cancer immunotherapy indicate a possibility of significantly lowering the cancer burden in South Africa. Among all cancer type, immunotherapy has worked best in the treatment of advanced melanoma and lung cancer. Nearly, 1 out of every 3 diagnosed cancer is melanoma.

Furthermore, it is estimated that 70% of all cancer cases will occur in developing countries by 2030. The alarming rise in cancer incidence rates has provoked global collaboration on cancer drugs and other therapies. For instance, the European Society of Medical Oncology held a summit in Cape Town, South Africa in March 2018 to discuss advancements in cancer treatment.

The introduction of immunotherapy has aided in saving 1 out of every 4 melanoma patients. Although the usage of immunotherapy is minimal as compared to chemotherapy, radiotherapy, and surgery, we anticipate immunotherapy to emerge as the leading treatment strategy for cancer over the next few years.